Home » Topics » BioWorld Science, Neurology/psychiatric

BioWorld Science, Neurology/psychiatric
RSS

NXP-031 leads to significant improvement of motor deficit in MPTP-induced mouse model of PD

Nov. 6, 2019

Cartesian initiates phase I/II study of its lead CAR-T candidate, Descartes-08

Nov. 6, 2019

Tau spreads quickly but kills slowly

Nov. 6, 2019

Japanese investigators patent CRF1 and CRF2 dual receptor antagonists

Nov. 5, 2019

Neuronal insulin resistance linked to age-related dementia

Nov. 4, 2019

Oligomannate approved in China for mild to moderate AD

Nov. 4, 2019

Promentis Pharmaceuticals announces update on phase II development of SXC-2023

Nov. 4, 2019

NTS2-selective compounds with promising activity in preclinical models of pain

Nov. 4, 2019

ACADIA Pharmaceuticals initiates phase III LAVENDER study of trofinetide in Rett syndrome

Oct. 31, 2019

FDA approves Vumerity for the treatment of multiple sclerosis

Oct. 31, 2019

Popular Stories

Today's news in brief
BioWorld
BioWorld briefs for May 22, 2026.
‘Detargeted’ targeted gene therapy improves activity in Pompe
BioWorld
A new strategy aims to improve gene therapy for Pompe disease by optimizing both the genetic component that restores the function of a deficient lysosomal enzyme...
News in brief
BioWorld Asia
BioWorld Asia briefs for May 19, 2026
Genescience presents STAT6 degrader for atopic dermatitis
BioWorld Science
Genescience Pharmaceutical Co. Ltd. has presented data on a new STAT6 PROTAC degrader – GenSciP166 – which selectively targets STAT6 for proteasomal degradation....
Roche reports new TREM2 agonists
BioWorld Science
F. Hoffmann-la Roche Ltd. and Hoffmann-La Roche Inc. have identified new triggering receptor expressed on myeloid cells 2 (TREM2) agonists potentially useful for...